UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Questioning Our APHINITY for More

The New England journal of medicine, 2017-07, Vol.377 (2), p.186-187

Miller, Kathy D

2017

Volltextzugriff (PDF)

Steel Toes and Stilettos: A True Story of Women Manufacturing Leaders and Lean Transformation Success

1, 2021

Volltextzugriff (PDF)

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2128-2135

2013

Volltextzugriff (PDF)

A New Look as JCO Looks to the Future

Journal of clinical oncology, 2023-07, Vol.41 (19), p.3478-3479

2023

Volltextzugriff (PDF)

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3234-3241

2012

Volltextzugriff (PDF)

Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening

JAMA : the journal of the American Medical Association, 2020-02, Vol.323 (8), p.746

2020

Volltextzugriff (PDF)

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Journal of clinical oncology, 2022-01, Vol.40 (3), p.282-293

2022

Volltextzugriff (PDF)

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

The lancet oncology, 2021-02, Vol.22 (2), p.212-222

2021

Volltextzugriff (PDF)

JCO Turns 40

Journal of clinical oncology, 2023-01, Vol.41 (1), p.1-2

2023

Volltextzugriff (PDF)

Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women

Journal of clinical oncology, 2023-03, Vol.41 (7), p.1339-1341

2023

Volltextzugriff (PDF)

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.884-890

2018

Volltextzugriff (PDF)

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

Cancer, 2014-08, Vol.120 (15), p.2237-2246

2014

Volltextzugriff (PDF)

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Clinical cancer research, 2018-07, Vol.24 (13), p.3163-3175

2018

Volltextzugriff (PDF)

Introducing Clinical Trial Updates

Journal of clinical oncology, 2022-05, Vol.40 (15), p.1599-1600

2022

Volltextzugriff (PDF)

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Journal of clinical oncology, 2014-12, Vol.32 (34), p.3840-3847

2014

Volltextzugriff (PDF)

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

Journal of clinical oncology, 2018-06, Vol.36 (16), p.1556-1563

2018

Volltextzugriff (PDF)

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

JAMA oncology, 2018-12, Vol.4 (12), p.1700

2018

Volltextzugriff (PDF)

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of clinical oncology, 2009-10, Vol.27 (30), p.4966-4972

2009

Volltextzugriff (PDF)

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4672-4678

2008

Volltextzugriff (PDF)

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Clinical cancer research, 2015-11, Vol.21 (22), p.5082-5091

2015

Volltextzugriff (PDF)

Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3‐arm pilot randomized controlled trial

Cancer, 2020-01, Vol.126 (1), p.211-218

2020

Volltextzugriff (PDF)

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

British journal of cancer, 2018-10, Vol.119 (9), p.1086-1093

2018

Volltextzugriff (PDF)

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3171-3181

2021

Volltextzugriff (PDF)

1 – 25 von 1.768

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.438)
Mit Volltextzugriff
(1.388)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.764)
Japanisch
(4)
Deutsch
(1)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Questioning Our APHINITY for More

Steel Toes and Stilettos: A True Story of Women Manufacturing Leaders and Lean Transformation Success

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

A New Look as JCO Looks to the Future

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

JCO Turns 40

Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Comparison of younger and older breast cancer survivors and age‐matched controls on specific and overall quality of life domains

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Introducing Clinical Trial Updates

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3‐arm pilot randomized controlled trial

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Suchergebnisse filtern